Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™: The Antares study

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of stent coatings in preventing early thrombotic occlusion remains to be proved. The purpose of this study was to evaluate the safety and efficacy of the Carbostent™, a new coronary stent with a nonthrombogenic coating (Carbofilm™), in 110 consecutive patients (73.6% men, mean age 61 ± 9 years) who met prespecified clinical and angiographic inclusion criteria and were treated with aspirin monotherapy after stenting. Stable angina (75.5%), unstable angina (18.2%), and silent ischemia (6.3%) were clinical indications for coronary revascularization. Patients received 10,000 U of heparin and no IIb/IIIa inhibitors or postprocedural heparin. Complex lesion characteristics (B2, C) were present in 39 out of 129 (30.2%) lesions. Mean lesion length was 15.6 ± 7.4 mm, and 32% of the lesions were >15 mm (range 16-52 mm). Small coronary vessels (

Original languageEnglish
Pages (from-to)150-156
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume55
Issue number2
DOIs
Publication statusPublished - 2002

Keywords

  • Antiplatelet therapy
  • Coated stents
  • Stent thrombosis
  • Thromboresistance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™: The Antares study'. Together they form a unique fingerprint.

Cite this